Memantine Augmentation in Obsessive-Compulsive Disorder

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Official Title

An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - at least 18 years of age - suffering from OCD - Y-BOCS score of 18 or greater - taking a therapeutic dose of an anti-OCD medication specified in the protocol
Exclusion Criteria:
  1. - diagnosed with a mental disorder other than OCD - taking tiagabine or pregabalin - having had a previous trial of memantine - receiving therapy for OCD - substance abuse in the last 6 months - personality disorders sufficiently severe to interfere with study participation


John Barry, MD
John Barry, MD
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult) and, by courtesy, of Neurology
Elias Aboujaoude, MD, MA
Clinical Professor, Psychiatry and Behavioral Sciences

Contact us to find out if this trial is right for you.


Nona Gamel